Despite a series of significant operational wins, shares of pharmaceutical giant Eli Lilly have recently experienced a notable downturn. This divergence between positive corporate developments and stock price movement has captured the attention of market participants.
Strategic FDA Approval and Research Investment
On December 3, the U.S. Food and Drug Administration granted full approval for the cancer treatment Jaypirca. This regulatory milestone allows the drug to be used for patients with chronic lymphocytic leukemia (CLL) who have undergone prior therapies. The decision carries strategic weight for the company, converting the therapy’s previous accelerated approval into a regular one and substantially widening its addressable patient population.
Concurrently, Eli Lilly is making a forward-looking research commitment. A new five-year partnership with Indiana University, valued at up to $40 million, is designed to accelerate clinical trials. The collaboration will concentrate on leveraging artificial intelligence to develop novel treatments for chronic diseases and Alzheimer’s.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Profit-Taking Pressure Creates Oversold Conditions
These fundamental positives, coupled with robust quarterly earnings—where revenue surged 54% year-over-year, driven by weight-loss drugs Mounjaro and Zepbound—have not shielded the equity from recent selling pressure. On a weekly basis, the stock declined 6.25%, closing Friday’s session at €866.10.
Market observers characterize this as a classic divergence. While analysts from firms like BMO Capital reaffirmed their “Outperform” rating, investors appear to have engaged in profit-taking. The Relative Strength Index (RSI) has fallen to a level of 28.5, moving into technically oversold territory. This indicator suggests the recent downward move may be overextended in the short term.
Upcoming Catalysts in Focus
Investor attention is now shifting to the next potential catalysts for the stock. Eli Lilly intends to submit its oral GLP-1 drug candidate, Orforglipron, to global regulators before the end of the year. A successful regulatory step in the competitive obesity market could trigger the next phase of growth and provide a fundamental conclusion to the current corrective phase.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from December 6 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 6.
Eli Lilly: Buy or sell? Read more here...
